Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann, L, Simpson, GR, Boxall, A, Kottke, T, Relph, KL, Vile, R, Melcher, A, Prestwich, R, Harrington, KJ, Morgan, R and Pandha, HS (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 11.
heinemann_et_al_BMC.pdf - Version of Record
Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in combination with other modalities such as chemotherapy, targeted therapy and radiotherapy. In this study, we examine the oncolytic activity of reovirus T3D and chemotherapeutic agents against human prostate cancer cell lines, with particular focus on the highly metastatic cell line PC3 and the chemotherapeutic agent docetaxel. Docetaxel is the standard of care for metastatic prostate cancer and acts by disrupting the normal process of microtubule assembly and disassembly. Reoviruses have been shown to associate with microtubules and may require this association for efficient viral replication.
|Divisions :||Faculty of Health and Medical Sciences > Microbial and Cellular Sciences|
|Identification Number :||10.1186/1471-2407-11-221|
|Additional Information :||© 2011 Heinemann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.|
|Depositing User :||Symplectic Elements|
|Date Deposited :||26 Jan 2012 12:18|
|Last Modified :||23 Sep 2013 18:59|
Actions (login required)
Downloads per month over past year